The AAPS Journal

, Volume 9, Issue 2, pp E117–E122 | Cite as

Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples

  • William NowatzkeEmail author
  • Eric Woolf


Characterization of the stability of analytes in biological samples collected during clinical studies together with that of critical assay reagents, including analyte stock solutions, is recognized as an important component of bioanalytical assay validation. Deficiencies in these areas often come to light during regulatory inspections. Best practices, based on current regulatory guidance, for the assessment of these issues as they pertain to ligand binding and chromatographic assays are covered in this review. Additionally, consensus recommendations reached during the recent AAPS/FDA Workshop on bioanalytical assay validation are highlighted.


Stability biological samples test article bioanalytical ligand binding assay chromatographic assay 


  1. 1.
    US Department of Health and Human Services, FDA, CDER, CVM.Guidance for the Industry: Bioanalytical Method Validation. Washington, DC: US Department of health and Human Services, FDA, CDER and CVM; 2001.Google Scholar
  2. 2.
    Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical method validation—a revisit with a decade of progress.Pharm Res. 2000;17:1551–1557.PubMedCrossRefGoogle Scholar
  3. 3.
    DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules.Pharm Res. 2003;20:1885–1900.PubMedCrossRefGoogle Scholar
  4. 4.
    Viswanathan CT, Bansal S, Booth B, et al. Workshop/conference report—quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays.AAPS J [serial online]. 2007;9:E30-E42.CrossRefGoogle Scholar
  5. 5.
    Yau M. Stability of samples, standards, QC's, and reagent: FDA perspective. Quantitative bioanalytical methods validation and implementation—best practices for chromatographic and ligand binding assays. Paper presented at the AAPS/FDA Workshop, May 2, 2006, Arlington, VA.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  1. 1.Department of Clinical Drug MetabolismMerck Research LaboratoriesWest Point
  2. 2.Department of Pharmacokinetics and Drug MetabolismAmgen, IncThousand Oaks

Personalised recommendations